Login to Access Video or Poster Abstract: MP53-04
Sources of Funding: Center for Healthy African American Men through Partnerships(CHAAMPS) Grant Number U54MD008620

Introduction

Studies have shown that systemic chemotherapy can improve survival in patient who develop castration resistant prostate cancer. We evaluate the time to chemotherapy from initiation of ADT by racial subgroups in men with prostate cancer.

Methods

We identified 81,579 men diagnosed with prostate cancer between 2004-2009 from the Surveillance, Epidemiology and End Results database (SEER). We then risk stratified the men based on the DAmico criteria. Those with one or more unknown tumor variables (prostate specific antigen, T stage and/or Gleason Score) were labeled unknown. Of this group, we identified 2370 men who received chemotherapy after ADT, 2137 non-Hispanic Caucasian and non-Hispanic 233 African American. Overall and risk-stratified analyses were performed using T-test and multiple linear regression which compared the time interval from diagnosis to chemotherapy and from initiation of ADT to initiation of chemotherapy in African Americans vs. Caucasians.

Results

The median time from diagnosis to chemotherapy was 32 months and from initiation of ADT to chemotherapy was 25 months. The median time from ADT to chemotherapy for the low risk group was 16 months (n= 119), intermediate risk was 29 months (n = 313), high risk 29 months (n = 920) and unknown 21 months (n = 1018). African American males had a median length of 18 months compared to Caucasian males 25 months (p value from t-test = 0.006). After adjusting for age, year of diagnosis, income, education, Charlson comorbidity score, and risk of prostate cancer, the difference is still significant: the least squares mean time from ADT to chemo is 22.5 months in AA vs. 27.5 months in CA (p=0.006).

Conclusions

The length of time from ADT to salvage chemotherapy in African American males is shorter compared to Caucasian males. This may suggest that AA men have cancers that progress faster on ADT compared to prostate cancer in Caucasian men.

Funding

Center for Healthy African American Men through Partnerships(CHAAMPS) Grant Number U54MD008620